FDA Warns Wyeth About Quality Issues

The Food and Drug Administration issued a warning letter to Wyeth (WYE) about quality control issues at its plant in Puerto Rico. Separately, Merrill Lynch analyst David Risinger downgraded the drug maker over concerns that drugs in the company's pipeline may not live up to expectations. The stock price lost $1.55 to close at $46.32.